332 related articles for article (PubMed ID: 25970686)
1. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
Rossi S; Gasparotto D; Miceli R; Toffolatti L; Gallina G; Scaramel E; Marzotto A; Boscato E; Messerini L; Bearzi I; Mazzoleni G; Capella C; Arrigoni G; Sonzogni A; Sidoni A; Mariani L; Amore P; Gronchi A; Casali PG; Maestro R; Dei Tos AP
Am J Surg Pathol; 2015 Jul; 39(7):922-30. PubMed ID: 25970686
[TBL] [Abstract][Full Text] [Related]
2. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
[TBL] [Abstract][Full Text] [Related]
3. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
[TBL] [Abstract][Full Text] [Related]
4. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
5. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
Lasota J; Miettinen M
Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
[TBL] [Abstract][Full Text] [Related]
6. [Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST)].
He HY; Fang WG; Zhong HH; Li Y; Zheng J; Du J; Heng WJ; Wu BQ
Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):262-6. PubMed ID: 16776995
[TBL] [Abstract][Full Text] [Related]
7. [Status and clinical analysis of c-kit and PDGFRA mutations in the gastrointestinal stromal tumors].
Du CY; Shi YQ; Zhou Y; Fu H; Zhao GF
Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul; 11(4):371-5. PubMed ID: 18636362
[TBL] [Abstract][Full Text] [Related]
8. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
Du CY; Shi YQ; Zhou Y; Fu H; Zhao G
J Surg Oncol; 2008 Sep; 98(3):175-8. PubMed ID: 18618605
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
[TBL] [Abstract][Full Text] [Related]
10. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Heinrich MC; Corless CL; Demetri GD; Blanke CD; von Mehren M; Joensuu H; McGreevey LS; Chen CJ; Van den Abbeele AD; Druker BJ; Kiese B; Eisenberg B; Roberts PJ; Singer S; Fletcher CD; Silberman S; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2003 Dec; 21(23):4342-9. PubMed ID: 14645423
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP
Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
Lasota J; Miettinen M
Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
14. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
[TBL] [Abstract][Full Text] [Related]
15. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
Martinho O; Gouveia A; Viana-Pereira M; Silva P; Pimenta A; Reis RM; Lopes JM
Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767
[TBL] [Abstract][Full Text] [Related]
16. [c-Kit and PDGFRA mutations and clinico-morphological features of gastrointestinal stromal tumors].
Beliakov IS; Anurova OA; Snigur PV; Tsyganova IV; Sel'chuk VIu; Mazurenko NN
Vopr Onkol; 2007; 53(6):677-81. PubMed ID: 18416137
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.
Lim KH; Huang MJ; Chen LT; Wang TE; Liu CL; Chang CS; Liu MC; Hsieh RK; Tzen CY
Med Oncol; 2008; 25(2):207-13. PubMed ID: 18488160
[TBL] [Abstract][Full Text] [Related]
18. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated.
Penzel R; Aulmann S; Moock M; Schwarzbach M; Rieker RJ; Mechtersheimer G
J Clin Pathol; 2005 Jun; 58(6):634-9. PubMed ID: 15917417
[TBL] [Abstract][Full Text] [Related]
19. Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors.
Tzen CY; Wang MN; Mau BL
Eur J Surg Oncol; 2008 May; 34(5):563-8. PubMed ID: 17532173
[TBL] [Abstract][Full Text] [Related]
20. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
